Acute pancreatitis induced by acute organophosphate poisoning?

P. G. Moore
M.B. B.S. (Syd.), F.F.A.R.A.C.S.

O. F. James
M.S. (Syd.), F.F.A.R.A.C.S., F.F.A.R.C.S.,
F.F.A.R.C.S.I.

Department of Anaesthesia and Intensive Care, The Royal Newcastle Hospital, Newcastle, Australia 2300

Summary
A 32-year-old male with acute organophosphate poisoning developed hyperglycaemia, glycosuria and ketonuria soon after admission to hospital. Serum amylase estimations suggested a diagnosis of acute pancreatitis. He required insulin therapy to control his hyperglycaemia and the organophosphate poisoning was successfully managed by artificial ventilation, an infusion of pralidoxime and intermittent atropine. He was discharged on the 17th hospital day with no permanent physical sequelae.

Introduction
The clinical manifestations and pharmacological management of acute organophosphate poisoning have been previously well described (Grob, 1956; Namba et al., 1971; Vale and Scott, 1974). However, this case report describes an unusual complication of acute organophosphate poisoning which contradicts the expected biochemical response.

Case report
A 32-year-old male accountant presented to the Emergency Ward of the Royal Newcastle Hospital after becoming ill at his place of employment. He had reported to his medical officer at work approximately 30 min before, complaining of nausea, dizzi-ness and abdominal cramps. During transport to hospital he became unconscious and developed generalized convulsions. The admitting resident medical officer administered intranasal oxygen and injected the following agents i.v.: diazepam 20 mg; phenytoin sodium 250 mg; clonazepam 1 mg; and dextrose 2.5 g. Because of slow (3 breaths/min) and inadequate respiration, artificial ventilation was commenced via an oral endotracheal tube. Arterial blood gas analysis before this showed a Pao2 80 mmHg, Paco2 106 mmHg, pH 6.913, base excess −15 mg/l.

Clinical examination following intubation revealed the following physical signs: systemic arterial BP (initially 90/50 mmHg) decreased to 50/− mmHg after positive pressure ventilation; heart rate 48 beats/min; profuse sweating, hypersalivation, rhinorrhoea, bronchorrhoea and lacrimation; incontinence of urine and faeces.

Neurological examination showed the following signs: an unconscious patient unresponsive to all stimuli; generalized flaccid paralysis and areflexia; fine muscular fasciculations; pinpoint unreactive pupils; absent oculocephalic and caloric reflexes.

With these clinical findings and the past history of chronic endogenous depression a provisional diagnosis of self-administered organophosphate poisoning was made. Blood was collected for serum cholinesterase assay, full blood count, serum electrolytes and liver function tests.

He was treated with atropine 0.6 mg i.v. with an immediate increase in pulse rate to 90 beats/min and BP to 135/65 mmHg. Pralidoxime 1 g i.v. was given and resulted in reduction in secretions from the nose, oropharynx, trachea and skin, spontaneous small movements of hands and feet and some return, though diminished, of tendon reflexes. He remained unconscious, unresponsive and without spontaneous respiratory efforts. When stabilized he was transferred to the Intensive Care Unit (ICU).

The finding of an empty bottle of coumaphos in the patient’s locker at work the day following admission confirmed the provisional diagnosis. The ingested dose of coumaphos (0,0-diethyl-0-3-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl phosphorothioate) was estimated to be 14 g. The calculated LD50 for this man who weighed 85 kg was 1.275 g (15 mg/kg).

Investigations
After admission to the ICU, ward urine test showed heavy glycosuria and moderate ketonuria. Blood glucose level at that time was 15 mmol/l (normal limit, <8.9 mmol/l non-fasting state) but was 29.8 mmol/l when reviewed 90 min later. Serum cholinesterase concentration was 60 u./l (normal range 3000–6000 u.l).
Serum amylase concentration 3·5 hr after admission was 1397 u./l (normal range 70–300 u./l). This decreased to 301 u./l when re-examined 20 hr after admission.

**Treatment and progress**

Soluble insulin 20 u. subcutaneously was given after the blood glucose was found to be 29·8 mmol/l and using a 'sliding scale' of soluble insulin a further 16 u. of soluble insulin was given in divided doses over the next 12 hr. Twenty hr after admission the blood glucose was 10·6 mmol/l. No further insulin was needed and thereafter the blood glucose stayed within normal limits and the urine remained free of sugar.

An infusion of phenytoin sodium 125 mg/hr maintained to control convulsions was discontinued 16 hr after admission. Diazepam in 5 mg i.v. injections was used to control muscle fasciculations in the first 24 hr.

Pralidoxime was given by infusion of 6 g/24 hr for 12 days. Atropine 0·6 mg was given by i.m. injection every 6 hr and additional atropine 9·6 mg was given by i.v. injection when the pulse rate fell below 70 beats/min. Atropine was needed for 8 days.

Continuous cardiac monitoring was employed and he needed artificial ventilation for a total of 6 days. By the 2nd hospital day he exhibited occasional slight spontaneous movements and responded to painful stimuli. On the 3rd day he responded to verbal commands and could move all limbs. Spontaneous shallow respiratory efforts had returned and he had a weak cough. He was then managed by intermittent mandatory ventilation which was gradually reduced over the next 3 days as adequate respirations returned. He gradually gained muscle strength but when his orotracheal tube was removed on the 6th day he had persisting proximal muscle weakness. His physical signs continued to improve and on the 17th day after admission he was discharged from the ICU for in-patient psychiatric care. At this time he had recovered muscle strength but complained of a 'dizzy' feeling and was occasionally incontinent of urine. His serial serum cholinesterase concentrations are shown in Fig. 1.

**Discussion**

The clinical effects of the anticholinesterase drugs are almost entirely due to the inhibition of acetylcholinesterase (AChE) whose physiological substrate is acetylcholine (ACh) (Namba et al., 1971). The organophosphate esters act by the formation of a stable acylated enzyme. This results in inactivation of AChE and the accumulation of large amounts of ACh at the cholinocceptive receptors. The resulting widespread effects can be conveniently separated into 4 main areas: potentiation of postganglionic parasympathetic (muscarinic) activity; persistent depolarization of skeletal muscle; initial stimulation of cells in the central nervous system followed by depression; variable autonomic ganglionic stimulation or blockade.

Management of this patient followed accepted principles (Vale and Scott, 1974) and included the use of atropine to alleviate the muscarinic and central nervous system manifestations of organophosphate poisoning, pralidoxime to improve the force of muscular contraction and artificial ventilation to maintain adequate gas exchange.

Organophosphate poisoning should also cause predictable biochemical effects as the autonomic nervous system, which is modified by organophosphate, plays an important role in the regulation of insulin secretion. Stimulation of the vagus nerve (Kaneto, Kosaka and Nakao, 1967; Frohman, Ezdini and Gavid, 1967) or the administration of parasympathomimetic agents (Malaisse et al., 1967; Kaneto et al., 1968) are both known to stimulate insulin secretion. Also vagotomy (Frohman et al., 1967) or cholinergic blockade (Permutt, Keller and Santiago, 1977) are known to inhibit insulin secretion (Permutt et al., 1977). Therefore, the expected response to organophosphate would be stimulation of insulin secretion and a reduction in the blood glucose concentration. This is supported in the report of a case of temporary remission of diabetes mellitus in a patient following organophosphate poisoning (Samantray, 1978).

The occurrence of hyperglycaemia, glycosuria and ketonuria in the subject of this report is therefore paradoxical. The use of i.v. glucose on admission
would have raised the blood glucose concentration temporarily but would not be sufficient to produce persistent hyperglycaemia. Also although anticholinergic agents are known to increase the blood glucose concentration in the normal patient this would not seem to be important in this patient in view of the severity of the poisoning and the degree of muscarinic stimulation present. The finding of a raised serum amylase may provide the explanation for this patient’s hyperglycaemia. This finding suggests that the patient may have developed an episode of acute pancreatitis which was mild and self-limiting. The clinical signs of such a process would have been masked by the overwhelming clinical manifestations of the organophosphate poisoning. The reasons why this patient might develop acute pancreatitis are unclear although the occurrence of severe circulatory collapse present in the initial phase of this patient’s poisoning is a possible explanation. Local effect of the organophosphate may also be a possibility. However, the finding of a raised serum amylase may not necessarily prove the diagnosis of acute pancreatitis (Takahashi et al., 1980). From theoretical analysis one would expect an increase in exocrine secretion of the pancreas and salivary glands in response to the increased muscarinic activity caused by the organophosphate. Whether this causes an abnormal increase in serum amylase is unknown. Thus the cause of the patient’s metabolic and pancreatic response to the organophosphate poisoning remains unproved.

References


Grob, D. (1956) The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterase compounds. Archives of Internal Medicine, 98, 221.


Acute pancreatitis induced by acute organophosphate poisoning?

P. G. Moore and O. F. James

doi: 10.1136/pgmj.57.672.660

Updated information and services can be found at:
http://pmj.bmj.com/content/57/672/660

Email alerting service

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/